Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/01/2026 ,inter alia, to consider and approve Pursuant to Regulation 30 of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has informed BSE that its Board will meet on 1 January 2026 to consider several major strategic items. The Board will evaluate a proposal to change the company's name to reflect a new business direction. It will also consider acquiring four target companies across pharmaceutical formulations, medical equipment manufacturing, electric vehicle (EV) manufacturing, and steel/tin sheets. Additionally, the Board plans to alter the Main Objects clause of the Memorandum of Association to allow diversification into EV manufacturing, steel/tin sheets trading, and solar energy equipment manufacturing and power generation. Shareholder and MCA approvals will be required for the name change and MOA amendment.
This signals a significant pivot away from the company's existing pharma-focused business into unrelated high-growth sectors like EVs, steel, and solar energy. Shareholders should watch the 1 January outcome closely, as approved acquisitions and a name change could materially alter the company's risk profile, valuation, and future earnings mix.